Limits...
Clinical impact of non-high density lipoprotein-cholesterol and apolipoprotein B on clinical outcomes in metabolic syndrome patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Ahmed K, Jeong MH, Chakraborty R, Hong YJ, Oh MS, Cho KH, Kim MC, Hachinohe D, Hwang SH, Lee MG, Sim DS, Park KH, Kim JH, Ahn Y, Kang JC - Korean Circ J (2012)

Bottom Line: Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes.Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

View Article: PubMed Central - PubMed

Affiliation: The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.

ABSTRACT

Background and objectives: Non-high density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (ApoB) are markers of atherosclerotic risk and predictors of cardiovascular events. The aim of this study was to evaluate clinical impact of non-HDL-C and ApoB on clinical outcomes in metabolic syndrome (MS) patients with acute myocardial infarction (AMI) undergoing percuatneous coronary intervetion.

Subjects and methods: We analyzed 470 MS patients (64.4±12.0 years, 53.6% male) with AMI who were followed-up for 12-month after percutaneous coronary intervention (PCI) from December 2005 to January 2008 in a single center. These patients were divided into 2 groups based on median values of non-HDL-C and ApoB. We studied their baseline and follow-up relation with 12-month clinical outcomes, all-cause death and major adverse cardiac events (MACE).

Results: Mean values of baseline non-HDL-C and ApoB were 141.2±43.1 mg/dL and 99.3±29.0 mg/dL respectively. During 12-month follow-up 32 MACE (6.8%) and 12 deaths (2.5%) occurred. We observed significant correlation between non-HDL-C and ApoB. Twelve-month MACE and all-cause death after PCI showed no significant relation as non-HDL-C or ApoB levels increased. Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes. Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.

Conclusion: There was no significant association between higher non-HDL-C or ApoB and 12-month clinical outcomes in MS patients with AMI undergoing PCI. ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

No MeSH data available.


Related in: MedlinePlus

ApoB reduction rates vs. 12-month major adverse cardiac events. AopB: apolipoprotein B.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3369963&req=5

Figure 3: ApoB reduction rates vs. 12-month major adverse cardiac events. AopB: apolipoprotein B.

Mentions: Reduction rate of non-HDL-C showed a decreasing trend of 12-month MACE, but it was not statistically significant {43.8% reduction in group A (0-10%) vs. 26.7% in group B (10-30%) vs. 19.0% in group C (>30%), p=0.069} as shown in Fig. 2. We noted that 12-month MACE also showed a decreasing trend as ApoB reduction rate increased {47.8% reduction in group A (0-10%) vs. 23.4% in group B (10-30%) vs. 16.2% in group C (>30%), p=0.004} as shown in Fig. 3. Prognostic value of the rates of ApoB reduction for 12-month MACE is presented in Table 5, when unadjusted showed significant relation with 12-month MACE (unadjusted p=0.012), 59% reduction in group B {0.417 (0.191-0.907), p=0.027} and 67% reduction in group C {0.331 (0.157-0.695), p=0.003}. It was also significant when adjusted with age and gender (Model 1), p=0.012, 57% reduction in group B {0.437 (0.199-0.958), p=0.039} and 68% reduction in group C {0.324 (0.153-0.683), p=0.003}. After adjustment with multiple covariates (Model 2), patients in group B had 57% reduction {0.431 (0.186-0.997), p=0.049} and patients in group C had 62% reduction {0.383 (0.171-0.855), p=0.019} for MACE at 12-month follow-up. The variables included in Model 2 were age, gender, creatinine, total cholesterol, triglyceride, Killip class, history of hyperlipidemia, clinical presentation with ST-elevation MI and ACC/AHA lesion type C.


Clinical impact of non-high density lipoprotein-cholesterol and apolipoprotein B on clinical outcomes in metabolic syndrome patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Ahmed K, Jeong MH, Chakraborty R, Hong YJ, Oh MS, Cho KH, Kim MC, Hachinohe D, Hwang SH, Lee MG, Sim DS, Park KH, Kim JH, Ahn Y, Kang JC - Korean Circ J (2012)

ApoB reduction rates vs. 12-month major adverse cardiac events. AopB: apolipoprotein B.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3369963&req=5

Figure 3: ApoB reduction rates vs. 12-month major adverse cardiac events. AopB: apolipoprotein B.
Mentions: Reduction rate of non-HDL-C showed a decreasing trend of 12-month MACE, but it was not statistically significant {43.8% reduction in group A (0-10%) vs. 26.7% in group B (10-30%) vs. 19.0% in group C (>30%), p=0.069} as shown in Fig. 2. We noted that 12-month MACE also showed a decreasing trend as ApoB reduction rate increased {47.8% reduction in group A (0-10%) vs. 23.4% in group B (10-30%) vs. 16.2% in group C (>30%), p=0.004} as shown in Fig. 3. Prognostic value of the rates of ApoB reduction for 12-month MACE is presented in Table 5, when unadjusted showed significant relation with 12-month MACE (unadjusted p=0.012), 59% reduction in group B {0.417 (0.191-0.907), p=0.027} and 67% reduction in group C {0.331 (0.157-0.695), p=0.003}. It was also significant when adjusted with age and gender (Model 1), p=0.012, 57% reduction in group B {0.437 (0.199-0.958), p=0.039} and 68% reduction in group C {0.324 (0.153-0.683), p=0.003}. After adjustment with multiple covariates (Model 2), patients in group B had 57% reduction {0.431 (0.186-0.997), p=0.049} and patients in group C had 62% reduction {0.383 (0.171-0.855), p=0.019} for MACE at 12-month follow-up. The variables included in Model 2 were age, gender, creatinine, total cholesterol, triglyceride, Killip class, history of hyperlipidemia, clinical presentation with ST-elevation MI and ACC/AHA lesion type C.

Bottom Line: Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes.Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

View Article: PubMed Central - PubMed

Affiliation: The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.

ABSTRACT

Background and objectives: Non-high density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (ApoB) are markers of atherosclerotic risk and predictors of cardiovascular events. The aim of this study was to evaluate clinical impact of non-HDL-C and ApoB on clinical outcomes in metabolic syndrome (MS) patients with acute myocardial infarction (AMI) undergoing percuatneous coronary intervetion.

Subjects and methods: We analyzed 470 MS patients (64.4±12.0 years, 53.6% male) with AMI who were followed-up for 12-month after percutaneous coronary intervention (PCI) from December 2005 to January 2008 in a single center. These patients were divided into 2 groups based on median values of non-HDL-C and ApoB. We studied their baseline and follow-up relation with 12-month clinical outcomes, all-cause death and major adverse cardiac events (MACE).

Results: Mean values of baseline non-HDL-C and ApoB were 141.2±43.1 mg/dL and 99.3±29.0 mg/dL respectively. During 12-month follow-up 32 MACE (6.8%) and 12 deaths (2.5%) occurred. We observed significant correlation between non-HDL-C and ApoB. Twelve-month MACE and all-cause death after PCI showed no significant relation as non-HDL-C or ApoB levels increased. Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes. Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.

Conclusion: There was no significant association between higher non-HDL-C or ApoB and 12-month clinical outcomes in MS patients with AMI undergoing PCI. ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

No MeSH data available.


Related in: MedlinePlus